Form 4: Amneal Pharmaceuticals Director Gautam Patel Sells 80,000 Shares

Gautam Patel, a director at Amneal Pharmaceuticals, sold 80,000 shares of Class A Common Stock on March 3, 2025, at an average price of $8.9 per share.

Summary

• On March 3, 2025, Gautam Patel, a director of Amneal Pharmaceuticals, Inc. (AMRX), sold 80,000 shares of Class A Common Stock.
• The sale was executed at a weighted average price of $8.9 per share.
• The transactions were conducted automatically under a pre-arranged trading plan adopted on August 15, 2024, in accordance with Rule 10b5-1(c).
• Following the reported transaction, Patel still beneficially owns 1,808,886 shares of Amneal Pharmaceuticals, Inc.

Sentiment

Score: 5

Explanation: The sentiment is neutral. It's a routine disclosure of a stock sale under a pre-arranged trading plan, with no explicit positive or negative implications.

Future Outlook

There is no future outlook provided in this document.

Industry Context

Form 4 filings are routine disclosures required by the SEC when corporate insiders, like directors and officers, trade their company's stock. These filings provide transparency into insider transactions, which can be closely watched by investors for signals about a company's prospects. It is common for insiders to use pre-arranged trading plans (Rule 10b5-1) to avoid accusations of trading on non-public information.

Comparison to Industry Standards

• Comparing this transaction to similar insider sales in the pharmaceutical industry requires analyzing the size of the sale relative to Patel's total holdings and the company's market capitalization.
• For example, if a director at Teva Pharmaceuticals (TEVA) or Mylan (now Viatris, VTRS) sold a similar percentage of their holdings, it would provide a benchmark for assessing the significance of Patel's sale.
• Additionally, examining the timing of the sale in relation to Amneal's stock performance and any recent company announcements is crucial for context.

Stakeholder Impact

• The sale of shares by a director could potentially create uncertainty among shareholders, although the existence of a pre-arranged trading plan mitigates this concern.

Key Dates